

In the claims:

1. (currently amended) A method of screening a human subject in need of treatment for a solid epithelial tumor that overexpresses ErbB2 ~~p185~~<sup>ErbB2</sup>, as an aid in selecting between therapy with Trastuzumab alone and Trastuzumab combined with GW572016, comprising determining whether the tumor expresses p95, where expression of p95 indicates said subject is more likely to exhibit a favorable clinical response to treatment that includes GW572016 than to treatment that does not include GW572016.
2. (original) A method according to claim 1 where expression of p95<sup>ErbB2</sup> in tumor tissue is assessed by immunohistochemical methods.
3. (original) A method according to claim 1 where expression of p95<sup>ErbB2</sup> is assessed by measuring ErbB2 extracellular domain (ECD) in the subject's serum.
4. – 5. (canceled).
6. (original) A method according to claim 1 where said tumor is selected from breast, ovarian, colon, head and neck, bladder, renal cell and lung tumors.
7. (original) A method according to claim 1 where said subject has breast cancer.
8. (canceled).
9. (original) A method according to claim 1 where said subject has previously been treated with trastuzumab.
10. – 28. (canceled).